Standout Papers

Multiple myeloma 2009 2026 2014 2020 526
  1. Multiple myeloma (2009)
    Marc S. Raab, Klaus Podar et al. The Lancet
  2. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma (2018)
    Meletios Α. Dimopoulos, Dominik Dytfeld et al. New England Journal of Medicine

Immediate Impact

8 by Nobel laureates 24 from Science/Nature 58 standout
Sub-graph 1 of 22

Citing Papers

Targeted protein degradation: from mechanisms to clinic
2024 Standout
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
2023 Standout
3 intermediate papers

Works of Marc S. Raab being referenced

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
2020
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
2018 Standout
and 4 more

Author Peers

Author Last Decade Papers Cites
Marc S. Raab 3452 3286 2368 199 5.3k
Peter M. Voorhees 2816 3201 2660 170 5.1k
Suzanne Trudel 2952 3341 2243 243 5.1k
Jacob P. Laubach 3845 3817 2622 229 5.9k
Suzanne Lentzsch 4709 4297 3252 219 6.9k
Andrzej Jakubowiak 3991 4056 2988 257 6.1k
Jérôme Moreaux 1924 2862 1442 167 4.7k
Jonathan L. Kaufman 5075 4854 3507 318 7.7k
Nizar J. Bahlis 4063 3652 2693 348 5.7k
Stéphane Minvielle 2681 3113 1600 146 4.4k
Karin Vanderkerken 3525 4399 3108 224 7.7k

All Works

Loading papers...

Rankless by CCL
2026